CY1115986T1 - Σταθερη σε υψηλη θερμοκρασια περιεχουσα φορεα οξυγονου φαρμακευτικη συνθεση - Google Patents
Σταθερη σε υψηλη θερμοκρασια περιεχουσα φορεα οξυγονου φαρμακευτικη συνθεσηInfo
- Publication number
- CY1115986T1 CY1115986T1 CY20151100114T CY151100114T CY1115986T1 CY 1115986 T1 CY1115986 T1 CY 1115986T1 CY 20151100114 T CY20151100114 T CY 20151100114T CY 151100114 T CY151100114 T CY 151100114T CY 1115986 T1 CY1115986 T1 CY 1115986T1
- Authority
- CY
- Cyprus
- Prior art keywords
- hemoglobin
- high temperature
- stable
- cross
- pharmaceutical composition
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/41—Porphyrin- or corrin-ring-containing peptides
- A61K38/42—Haemoglobins; Myoglobins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/795—Porphyrin- or corrin-ring-containing peptides
- C07K14/805—Haemoglobins; Myoglobins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Cardiology (AREA)
- Virology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Developmental Biology & Embryology (AREA)
- Urology & Nephrology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Oncology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Μια σταθερή σε υψηλή θερμοκρασία και υψηλής καθαρότητας διασυνδεδεμένη (κατ' επιλογή>70% β-β συνδεδεμένη) τετραμερής αιμοσφαιρίνη με υψηλή απόδοση παροχής οξυγόνου κατάλληλη για χρήση σε θηλαστικά χωρίς πρόκληση νεφρικής βλάβης και αγγειοσυστολής παρέχεται. Η διμερής μορφή της αιμοσφαιρίνης είναι εκφυλισμένη και διαδικασίες καθαρισμού πραγματοποιούνται σε ερυθρά αιμοσφαίρια από πλήρες αίμα. Η ελεγχόμενη υποτονική λύση σε μια συσκευή άμεσης κυτταρόλυσης αποτρέπει λύση λευκών αιμοσφαιρίων. Νουκλεϊκά οξέα από λευκά αιμοσφαίρια και προσμείξεις φωσφολιπιδίων δεν ανιχνεύονται. Μπλοκάρισμα των αντιδραστικών σουλφυδρυλικών ομάδων με ένα σουλφυδρυλικό αντιδραστήριο πραγματοποιείται σε ένα οξυγονωμένο περιβάλλον. Χρωματογραφία στήλης διερχόμενου ρεύματος απομακρύνει διαφορετικές πρωτεϊνικές προσμείξεις του πλάσματος. Ν-ακετυλο κυστεΐνη προστίθεται στη διασυνδεδεμένη τετραμερή αιμοσφαιρίνη για να διατηρηθεί ένα χαμηλό επίπεδο met-αιμοσφαιρίνης. Η σταθεροποιημένη αιμοσφαιρίνη διατηρείται σε έναν σάκο έγχυσης με περιτύλιγμα αλουμινίου για πρόληψη του σχηματισμού αδρανούς met-αιμοσφαιρίνης από παρείσφρηση οξυγόνου. Το προϊόν βρίσκει χρήση σε οξυγόνωση ιστών και αντιμετώπιση καρκίνου.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US34876410P | 2010-05-27 | 2010-05-27 | |
US13/013,847 US8742073B2 (en) | 2010-05-27 | 2011-01-26 | Method for the preparation of a high-temperature stable oxygen-carrier-containing pharmaceutical composition and the use thereof |
US13/083,639 US7989593B1 (en) | 2010-05-27 | 2011-04-11 | Method for the preparation of a high-temperature stable oxygen-carrier-containing pharmaceutical composition and the use thereof |
EP11746429.7A EP2411025B1 (en) | 2010-05-27 | 2011-04-15 | High-temperature stable oxygen-carrier-containing pharmaceutical composition |
Publications (1)
Publication Number | Publication Date |
---|---|
CY1115986T1 true CY1115986T1 (el) | 2017-01-25 |
Family
ID=44314337
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20151100114T CY1115986T1 (el) | 2010-05-27 | 2015-02-04 | Σταθερη σε υψηλη θερμοκρασια περιεχουσα φορεα οξυγονου φαρμακευτικη συνθεση |
Country Status (21)
Country | Link |
---|---|
US (1) | US7989593B1 (el) |
EP (1) | EP2411025B1 (el) |
JP (1) | JP5261806B2 (el) |
KR (1) | KR101185437B1 (el) |
CN (2) | CN102405051B (el) |
AR (1) | AR081222A1 (el) |
AU (1) | AU2011221433B2 (el) |
CA (1) | CA2752943C (el) |
CY (1) | CY1115986T1 (el) |
DK (1) | DK2411025T3 (el) |
ES (1) | ES2527608T3 (el) |
HK (2) | HK1160604A1 (el) |
NZ (1) | NZ594915A (el) |
PL (1) | PL2411025T3 (el) |
PT (1) | PT2411025E (el) |
RU (1) | RU2475252C1 (el) |
SA (1) | SA111320476B1 (el) |
SG (1) | SG182237A1 (el) |
TW (1) | TWI377947B (el) |
WO (1) | WO2011149602A1 (el) |
ZA (1) | ZA201208726B (el) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8048856B1 (en) * | 2010-06-23 | 2011-11-01 | Billion King, Ltd. | Treatment methods using a heat stable oxygen carrier-containing pharmaceutical composition |
US8084581B1 (en) | 2011-04-29 | 2011-12-27 | Bing Lou Wong | Method for removing unmodified hemoglobin from cross-linked hemoglobin solutions including polymeric hemoglobin with a high temperature short time heat treatment apparatus |
US20130052232A1 (en) * | 2011-08-31 | 2013-02-28 | Bing Lou Wong | Method for the preparation of a heat stable oxygen carrier-containing composition facilating beta-beta cross-linking |
EP2753350A4 (en) | 2011-09-06 | 2015-02-18 | Bing Lou Wong | ORAL ADMINISTRATION FOR OXYGEN TRANSPORTERS BASED ON HEMOGLOBIN |
US20140106004A1 (en) * | 2012-10-12 | 2014-04-17 | Bing Lou Wong | Hemoglobin-based oxygen carrier-containing pharmaceutical composition for cancer targeting treatment and prevention of cancer recurrence |
CN103251998B (zh) * | 2012-11-08 | 2015-09-02 | 亿京国际有限公司 | 用于血红蛋白氧载体(hboc)溶液的精确输注递送系统 |
CN105408354B (zh) | 2013-01-07 | 2020-09-18 | 欧姆尼奥克斯公司 | H-nox蛋白的多聚形式 |
MX362001B (es) * | 2013-05-13 | 2019-01-03 | Vision Global Holdings Ltd | Composición farmacéutica que comprende un agente terapéutico a base de hemoglobina modificada para tratamiento dirigido al cáncer e imagenología diagnóstica. |
US9814759B2 (en) | 2014-07-02 | 2017-11-14 | Cheer Global Ltd. | Pharmaceutical composition comprising recombinant hemoglobin protein or subunit-based therapeutic agent for cancer targeting treatment |
SG10201908269SA (en) * | 2015-03-17 | 2019-10-30 | Omniox Inc | Modulation of tumor immunity by protein-mediated o2 delivery |
US9763889B2 (en) | 2015-06-29 | 2017-09-19 | Billion King International Ltd. | Oral delivery system for hemoglobin based oxygen carriers |
US10052290B2 (en) | 2016-02-04 | 2018-08-21 | Billion King International Ltd. | Enteric-coated hemoglobin multiparticulate for oral delivery of hemoglobin based oxygen carriers |
CN106421805B (zh) * | 2016-09-14 | 2019-06-04 | 中国人民解放军军事医学科学院野战输血研究所 | 一种右旋糖酐交联血红蛋白氧载体及其制备方法与应用 |
WO2020080978A2 (ru) * | 2018-10-19 | 2020-04-23 | Рахимджан Ахметджанович РОЗИЕВ | Cпособ получения кровезаменителя для применения в ветеринарии |
CA3149234A1 (en) * | 2019-08-29 | 2021-03-04 | Kwok Chu Butt | Thiosuccinyl-crosslinked hemoglobin analogs and methods of use and preparation thereof |
CN113621055B (zh) * | 2021-08-23 | 2023-05-02 | 山东仙普爱瑞科技股份有限公司 | 一种抗菌和抗病毒的猪血红蛋白β链C端片段、表达该片段的枯草芽孢杆菌、制剂以及应用 |
CA3231611A1 (en) * | 2021-09-17 | 2023-03-23 | Nenad SESTAN | Methods, systems and compositions for restoration and preservation of intact organs in a mammal |
Family Cites Families (66)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4529719A (en) | 1983-05-04 | 1985-07-16 | Tye Ross W | Modified crosslinked stroma-free tetrameric hemoglobin |
FR2548671B1 (fr) | 1983-07-07 | 1986-05-02 | Merieux Inst | Procede de preparation de globine a partir d'hemoglobine et globine obtenue par ce procede |
US4831012A (en) | 1984-03-23 | 1989-05-16 | Baxter International Inc. | Purified hemoglobin solutions and method for making same |
US4598064A (en) | 1984-06-27 | 1986-07-01 | University Of Iowa Research Foundation | Alpha-alpha cross-linked hemoglobins |
USRE34271E (en) | 1984-06-27 | 1993-06-01 | University Of Iowa Research Foundation | Production of alpha-alpha cross-linked hemoglobins in high yield |
US4600531A (en) | 1984-06-27 | 1986-07-15 | University Of Iowa Research Foundation | Production of alpha-alpha cross-linked hemoglobins in high yield |
JPH0750329B2 (ja) | 1986-06-23 | 1995-05-31 | 富士写真フイルム株式会社 | 画像形成材料 |
US5955581A (en) | 1986-11-10 | 1999-09-21 | Biopure Corporation | Method for producing a stable polymerized hemoglobin blood-substitute |
US5753616A (en) | 1986-11-10 | 1998-05-19 | Biopure Corporation | Method for producing a stable polymerized hemoglobin blood-substitute |
CA1312009C (en) | 1986-11-10 | 1992-12-29 | Carl W. Rausch | Extra pure semi-synthetic blood substitute |
US5084558A (en) | 1987-10-13 | 1992-01-28 | Biopure Corporation | Extra pure semi-synthetic blood substitute |
US5189146A (en) | 1987-05-05 | 1993-02-23 | Her Majesty The Queen In Right Of Canada, As Represented By The Minister Of National Defence | Pasteurizable, freeze-driable hemoglobin-based blood substitute |
US6150506A (en) * | 1989-05-10 | 2000-11-21 | Baxter Biotech Technology Sarl | Modified hemoglobin-like compounds and methods of purifying same |
US5439882A (en) | 1989-12-29 | 1995-08-08 | Texas Tech University Health Sciences Center | Blood substitute |
US5250665A (en) | 1991-05-31 | 1993-10-05 | The University Of Toronto Innovations Foundation | Specifically β-β cross-linked hemoglobins and method of preparation |
US5344393A (en) | 1992-02-28 | 1994-09-06 | Alliance Pharmaceutical Corp. | Use of synthetic oxygen carriers to facilitate oxygen delivery |
US6187744B1 (en) | 1992-03-11 | 2001-02-13 | Michael W. Rooney | Methods and compositions for regulating the intravascular flow and oxygenating activity of hemoglobin in a human or animal subject |
US5399671A (en) * | 1992-11-18 | 1995-03-21 | Kluger; Ronald | Specifically crosslinked hemoglobin with free functionality |
US5840851A (en) | 1993-07-23 | 1998-11-24 | Plomer; J. Jeffrey | Purification of hemoglobin |
US5817632A (en) | 1993-08-16 | 1998-10-06 | Hsia; Jen-Chang | Compositions and methods utilizing nitroxides in combination with biocompatible macromolecules |
US5840701A (en) | 1993-08-16 | 1998-11-24 | Hsia; Jen-Chang | Compositions and methods utilizing nitroxides in combination with biocompatible macromolecules |
US5804561A (en) | 1993-08-16 | 1998-09-08 | Hsia; Jen-Chang | Compositions and methods utilizing nitroxides in combination with biocompatible macromolecules |
US5824781A (en) | 1993-08-16 | 1998-10-20 | Hsia; Jen-Chang | Compositions and methods utilizing nitroxides in combination with biocompatible macromolecules |
US5767089A (en) | 1993-08-16 | 1998-06-16 | Hsia; Jen-Chang | Compositions and methods utilizing nitroxides in combination with biocompatible macromolecules |
TW381022B (en) | 1993-08-16 | 2000-02-01 | Hsia Jen Chang | Compositions and methods utilizing nitroxides to avoid oxygen toxicity, particularly in stabilized, polymerized, conjugated, or encapsulated hemoglobin used as a red cell substitute |
US5725839A (en) | 1993-08-16 | 1998-03-10 | Hsia; Jen-Chang | Compositions and methods utilizing nitroxides in combination with biocompatible macromolecules for ERI or MRI |
US5741893A (en) | 1993-08-16 | 1998-04-21 | Hsia; Jen-Chang | Compositions and methods utilizing nitroxides in combination with biocompatible macromolecules |
US5807831A (en) | 1993-08-16 | 1998-09-15 | Hsia; Jen-Chang | Compositions and methods utilizing nitroxides in combination with biocompatible macromolecules |
US5631219A (en) | 1994-03-08 | 1997-05-20 | Somatogen, Inc. | Method of stimulating hematopoiesis with hemoglobin |
US6242417B1 (en) | 1994-03-08 | 2001-06-05 | Somatogen, Inc. | Stabilized compositions containing hemoglobin |
WO1995031727A1 (en) | 1994-05-13 | 1995-11-23 | Therasorb Medizinische Systeme Gmbh | Sterile and pyrogen-free columns coupled to protein for binding and removal of substances from blood |
SE9500724D0 (sv) | 1994-06-23 | 1995-02-24 | Pharmacia Ab | Filtrering |
US6610832B1 (en) | 1995-03-23 | 2003-08-26 | Biopure Corporation | Preserving a hemoglobin blood substitute with a transparent overwrap |
EP1211261A3 (en) * | 1995-03-23 | 2004-03-17 | Biopure Corporation | Stable polymerized hemoglobin blood-substitute |
US5895810A (en) | 1995-03-23 | 1999-04-20 | Biopure Corporation | Stable polymerized hemoglobin and use thereof |
US6288027B1 (en) | 1995-03-23 | 2001-09-11 | Biopure Corporation | Preserving a hemoglobin blood substitute with a transparent overwrap |
US5691453A (en) | 1995-06-07 | 1997-11-25 | Biopure Corporation | Separation of polymerized hemoglobin from unpolymerized hemoglobin on hydroxyapatite using HPLC |
US5865784A (en) | 1995-06-07 | 1999-02-02 | Alliance Pharmaceutical Corp. | Method of hemodilution facilitated by monitoring oxygenation status |
AU1083497A (en) | 1995-11-30 | 1997-06-19 | Somatogen, Inc. | Method for control of functionality during cross-linking of hemoglobins |
JP2000506462A (ja) | 1996-03-21 | 2000-05-30 | ゼンゲバルト フェアパックンゲン ゲーエムベーハー | 多層フィルム、その製造方法、およびその使用方法 |
WO1997039761A1 (en) | 1996-04-19 | 1997-10-30 | Alpha Therapeutic Corporation | A process for viral inactivation of lyophilized blood proteins |
RU2080865C1 (ru) * | 1996-07-08 | 1997-06-10 | Станислав Людвигович Люблинский | Способ получения гемоглобина |
JP2002513400A (ja) * | 1997-02-06 | 2002-05-08 | デューク ユニバーシティ メディカル センター | No修飾ヘモグロビンおよびそのための使用 |
US6054427A (en) | 1997-02-28 | 2000-04-25 | The Regents Of The University Of California | Methods and compositions for optimization of oxygen transport by cell-free systems |
US5814601A (en) | 1997-02-28 | 1998-09-29 | The Regents Of The University Of California | Methods and compositions for optimization of oxygen transport by cell-free systems |
DE69826521T2 (de) | 1998-01-06 | 2005-09-29 | Cerus Corp., Concord | Verfahren zum quenchen von pathogen-inaktivatoren in biologischen materialien |
CA2233725A1 (en) * | 1998-03-31 | 1999-09-30 | Hemosol Inc. | Hemoglobin-hydroxyethyl starch complexes |
US6894150B1 (en) | 1999-10-01 | 2005-05-17 | Ross Walden Tye | Non-pyrogenic, endotoxin-free, stroma-free tetrameric hemoglobin |
US6747132B2 (en) | 2000-11-29 | 2004-06-08 | Apex Biosciences, Inc. | Methods for the synthesis of a modified hemoglobin solution |
US6518010B2 (en) | 2001-02-28 | 2003-02-11 | Biopure Corporation | Use of defibrinated blood for manufacture of a hemoglobin-based oxygen carrier |
KR20030097834A (ko) | 2001-04-18 | 2003-12-31 | 노쓰필드 라보라토리스, 인코포레이티드 | 안정화된 헤모글로빈 용액을 저장하기 위한 가요성 용기시스템 |
JP4260417B2 (ja) | 2001-05-23 | 2009-04-30 | ノバルティス アクチエンゲゼルシャフト | 溶液を輸送し脱酸素するためのシステム及び方法 |
US7038016B2 (en) | 2001-08-21 | 2006-05-02 | Apex Bioscience, Inc. | Methods for purification of an activated PEG solution and for the synthesis of a modified hemoglobin solution |
US20030153491A1 (en) | 2002-01-11 | 2003-08-14 | Winslow Robert M. | Methods and compositions for oxygen transport comprising a high oxygen affinity modified hemoglobin |
US20050164915A1 (en) | 2002-04-01 | 2005-07-28 | Sangart, Inc. | Compositions for oxygen transport comprising a high oxygen affinity modified hemoglobin |
AU2003299700B2 (en) | 2002-12-23 | 2009-03-26 | Albert Einstein College Of Medicine Of Yeshiva University | Modified hemoglobin and methods of making same |
US7135553B2 (en) | 2003-01-29 | 2006-11-14 | Northfield Laboratories, Inc. | Polymerized hemoglobin solutions having reduced amounts of tetramer and method for preparing |
US7135554B1 (en) * | 2004-01-27 | 2006-11-14 | Biopure Corporation | Method of forming a polymerized hemoglobin solution from stabilized hemoglobin |
DK1838355T3 (da) | 2004-10-29 | 2013-10-28 | Cerus Corp | Forbedrede quenching-fremgangsmåder til erytrocyt-inaktiveringsfremgangsmåde |
WO2007065265A1 (en) | 2005-12-08 | 2007-06-14 | Ronald Kluger | Cross-linking reagents for hemoglobin and hemoglobin products cross-linked therewith |
US7759306B2 (en) | 2006-05-16 | 2010-07-20 | Simoni Jan S | Methods of treating acute blood loss |
US7795401B2 (en) | 2006-09-06 | 2010-09-14 | National Chung Cheng University | Modified hemoglobin with allosteric effector conjugated |
CN101168565A (zh) * | 2006-10-23 | 2008-04-30 | 爱科有限公司 | 一氧化氮阻断的交联四聚体血红蛋白 |
US7494974B2 (en) | 2006-10-24 | 2009-02-24 | Ikor, Inc. | Carboxymethylated cross-linked tetrameric hemoglobin |
US7504377B2 (en) | 2006-10-23 | 2009-03-17 | Ikor, Inc. | Nitric oxide-blocked cross-linked tetrameric hemoglobin |
US7932356B1 (en) | 2010-06-23 | 2011-04-26 | Bing Lou Wong | Method for the preparation of a heat stable oxygen carrier-containing pharmaceutical composition |
-
2011
- 2011-04-11 US US13/083,639 patent/US7989593B1/en not_active Expired - Fee Related
- 2011-04-15 SG SG2011062502A patent/SG182237A1/en unknown
- 2011-04-15 CN CN2011800012855A patent/CN102405051B/zh active Active
- 2011-04-15 ES ES11746429.7T patent/ES2527608T3/es active Active
- 2011-04-15 CA CA2752943A patent/CA2752943C/en active Active
- 2011-04-15 AU AU2011221433A patent/AU2011221433B2/en active Active
- 2011-04-15 PT PT117464297T patent/PT2411025E/pt unknown
- 2011-04-15 PL PL11746429T patent/PL2411025T3/pl unknown
- 2011-04-15 CN CN201310054976.2A patent/CN103169954B/zh not_active Expired - Fee Related
- 2011-04-15 EP EP11746429.7A patent/EP2411025B1/en active Active
- 2011-04-15 KR KR1020117020242A patent/KR101185437B1/ko active IP Right Grant
- 2011-04-15 RU RU2011136158/15A patent/RU2475252C1/ru not_active IP Right Cessation
- 2011-04-15 DK DK11746429.7T patent/DK2411025T3/en active
- 2011-04-15 JP JP2012517937A patent/JP5261806B2/ja active Active
- 2011-04-15 WO PCT/US2011/032594 patent/WO2011149602A1/en active Application Filing
- 2011-04-15 NZ NZ594915A patent/NZ594915A/xx unknown
- 2011-04-29 TW TW100115051A patent/TWI377947B/zh active
- 2011-05-24 SA SA111320476A patent/SA111320476B1/ar unknown
- 2011-05-24 AR ARP110101773A patent/AR081222A1/es unknown
-
2012
- 2012-02-02 HK HK12100981.7A patent/HK1160604A1/xx unknown
- 2012-07-10 HK HK12106776.3A patent/HK1166258A1/xx not_active IP Right Cessation
- 2012-11-20 ZA ZA2012/08726A patent/ZA201208726B/en unknown
-
2015
- 2015-02-04 CY CY20151100114T patent/CY1115986T1/el unknown
Also Published As
Publication number | Publication date |
---|---|
JP5261806B2 (ja) | 2013-08-14 |
DK2411025T3 (en) | 2015-02-16 |
CN102405051B (zh) | 2013-01-23 |
SG182237A1 (en) | 2012-08-30 |
EP2411025B1 (en) | 2014-11-05 |
AU2011221433A1 (en) | 2011-12-15 |
PL2411025T3 (pl) | 2015-04-30 |
WO2011149602A8 (en) | 2012-05-24 |
CN103169954B (zh) | 2016-01-20 |
HK1166258A1 (en) | 2012-10-26 |
SA111320476B1 (ar) | 2013-07-28 |
TWI377947B (en) | 2012-12-01 |
CN103169954A (zh) | 2013-06-26 |
NZ594915A (en) | 2013-06-28 |
TW201141493A (en) | 2011-12-01 |
PT2411025E (pt) | 2015-02-04 |
JP2012526859A (ja) | 2012-11-01 |
CA2752943A1 (en) | 2011-11-27 |
AU2011221433B2 (en) | 2012-03-29 |
CA2752943C (en) | 2013-10-08 |
EP2411025A4 (en) | 2012-11-14 |
US7989593B1 (en) | 2011-08-02 |
HK1160604A1 (en) | 2012-08-10 |
KR20110138215A (ko) | 2011-12-26 |
ES2527608T3 (es) | 2015-01-27 |
CN102405051A (zh) | 2012-04-04 |
KR101185437B1 (ko) | 2012-10-02 |
AR081222A1 (es) | 2012-07-04 |
EP2411025A1 (en) | 2012-02-01 |
ZA201208726B (en) | 2013-09-25 |
RU2475252C1 (ru) | 2013-02-20 |
WO2011149602A1 (en) | 2011-12-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1115986T1 (el) | Σταθερη σε υψηλη θερμοκρασια περιεχουσα φορεα οξυγονου φαρμακευτικη συνθεση | |
Mard et al. | Gastroprotective effect of NaHS against mucosal lesions induced by ischemia–reperfusion injury in rat | |
EA201101155A1 (ru) | Способ приготовления фармацевтической композиции, содержащей теплостойкий переносчик кислорода | |
Chen et al. | Hydrogen-rich saline alleviates kidney fibrosis following AKI and retains Klotho expression | |
EA201400020A1 (ru) | Фармацевтическая композиция, содержащая термостойкий переносчик кислорода, для различных применений в лечебных целях | |
Baldwin | Modified hemoglobins produce venular interendothelial gaps and albumin leakage in the rat mesentery | |
Zhao et al. | Erastin‑induced ferroptosis causes physiological and pathological changes in healthy tissues of mice | |
Ye et al. | Inhibition of histone deacetylase 7 reverses concentrative nucleoside transporter 2 repression in colorectal cancer by up‐regulating histone acetylation state | |
Sakai et al. | Oxygen release from low and normal P50 Hb vesicles in transiently occluded arterioles of the hamster window model | |
Pinto et al. | Modulation of immunologic response by preventive everolimus application in a rat CPB model | |
Cabrales et al. | Tissue oxidative metabolism after extreme hemodilution with PEG-conjugated hemoglobin | |
Leng et al. | MICU1 may be a promising intervention target for gut-derived sepsis induced by intra-abdominal hypertension | |
Ratanasopa | Human Fetal Hemoglobin: Biochemical Characterization and Recombinant Production | |
Lu et al. | Application of Raman spectroscopy to the research on hemoglobin structure and function | |
Li et al. | Mitochondrial homeostasis: shaping health and disease | |
Janic et al. | The “Rise–Peak–Fall” Pattern of Time Dependency of the Cardiovascular Pleiotropic Effects of Treatment With Low-dose Atorvastatin, Losartan, and a Combination Thereof in Rats | |
Fei et al. | Burn injury differentially alters whole-blood and organ glutathione synthesis rates: An experimental model | |
Zhao et al. | Anti-cancer effects of trypsin inhibitor targeting glucose-regulated protein 78 (GRP78) in colorectal cancer cells | |
Meshchaninov et al. | Passport and biological age in the choice of metabolic geroprophylactic therapy | |
Swi Chang | Safety of red blood cell substitutes as compared to stored donor red blood cells | |
Balint | Toxic epidermal necrolysis: case report | |
Lier et al. | Stress-induced exit from dormancy alters redox signaling in HSCs, resulting in de novo DNA damage and bone marrow failure in the absence of a functional fanconi anemia signaling pathway | |
Yamashita | The present state and future of dry powder inhalation system | |
Cata | Reply from the author | |
TH171862A (th) | องค์ประกอบทางเภสัชกรรมที่มีสารตัวพาของออกซิเจนที่เสถียรต่อความร้อน สำหรับการประยุกต์ใช้ในการบำบัดที่แตกต่างกัน |